Innovative Medicine Initiatives (IMI)
Innovative Medicine Initiatives (IMI) is a large public private partnership aiming to develop next generation vaccines, medicines and treatments, such as new antibiotics.
In 2021 the IMI will be succeeded by the Innovative Health Initiative (IHI), a new Private Private Partnership program. We are awaiting further information on this program.
To get free funding updates, including the new IHI program, subscribe to Catalyze Alerts.
The aims of the IMI include:
- Improve the current drug development process
- Develop diagnostic and treatment biomarkers for diseases
- Reduce the time to reach clinical proof of concept in medicine development
- Increase the success rate in clinical trials of priority medicines identified by the WHO
- Develop new therapies for diseases for which there is a high unmet need
- Reduce the failure rate of vaccine candidates in phase III clinical trials
The private pharmaceutical companies, the EFPIA consortium, provide half of the project budget with in kind support (like personnel, samples, compounds, data, financial contribution and/or subcontracting). The money for the applicants comes from the Horizon 2020 budget for the first Societal Challenge.
The application process of IMI is quite extensive and exists of multiple steps:
- Submit a pre-proposal with your consortium consisting of academia, SMEs, patient organizations, regulatory agencies, HTA. This consortium is not including the EFPIA consortium.
- After review, the highest ranked proposal is selected to proceed towards the second stage
- Together with your own consortium and the EFPIA consortium the full proposal is submitted.
Returning Clinical Trial Data to Study Participants within a GDPR compliant and approved framework (RIA)
Scope: This project has two main objectives, which are equally important:
- The first one is to align local and pan-European implementations and best practice for handling personal data protection regulations in order to harmonise the legal framework applicable to medical research;
- The second one is to deliver a pan-European prototype process to return clinical trial data to study participants. This prototype process will be delivered as part of the project alongside a robust business plan to ensure its sustainability.
Modelling the impact of monoclonal antibodies and vaccines on the reduction of antimicrobial resistance (RIA)
Scope: The goal of the project is to develop a framework for setting up antimicrobial resistance (AMR)-focused economic evaluations of vaccines and mAbs.
The challenges include a measurement of the present rate of growth of AMR, its main drivers, its health and economic consequences, and which a vaccines and mAbs might have the best chance of reducing the rate of AMR growth and the related health and economic consequences.
A platform for accelerating biomarker discovery and validation to support therapeutics development for neurodegenerative diseases (RIA)
Scope: At the short proposal stage, applicants should address all the five objectives:
- Create a set of agreed principles to enable sharing and access to data and samples;
- Establish a network that can house high quality data and samples, which could have federated and centralised elements;
- Establish fair and transparent governance and processes specifically to enable sharing and access to data and samples;
- Test the above with the defined case studies and apply the learnings to fine-tune processes and use the outcomes to grow the platform;
- This platform must be a self-sustainable entity by the end of the project.
Optimal treatment for patients with solid tumours in Europe through Artificial Intelligence (RIA)
Scope: The scope of this call topic is to establish guideline-based decision support and platform solutions to generate knowledge discovery for breast, lung and prostate cancer with applicability to other indications, in several European ‘model’ regions.
Objective 1: Establish a guideline-based decision support for prioritized indications.
Objective 2: Establish a structured and interoperable data platform to unlock real-world-data potential in an oncology network.
Objective 3: Leverage the real world data gathered by the action to establish an AI-knowledge base and support treatment decisions for prioritized indications.
Shortening the path to Rare Disease diagnosis by using new born genetic screening and digital technologies (RIA)
Scope: The proposed project addresses the RD conundrum by focusing on shortening the path to diagnosis for RD patients.
The overall objective of this call topic is to shorten the path to RD diagnosis by using new-born / paediatric (infants during their first weeks of life) genetic screening; and, via application of advanced digital technologies that enable rare disease suspicion / identification. The latter might require consolidation of existing fragmented efforts.
Behavioural Model of Factors Affecting Patient Adherence (RIA)
Scope: The aims of the topic are to:
- develop a comprehensive understanding of the factors which affect patient needs and adherence,
- independently from the therapeutic area (i.e. generic or disease-agnostic), in a real-world context (as opposed to clinical setting),
- identify the most significant factors,
- evaluate existing models and then either create an open access behavioural model or further develop an existing model
- collect additional real-world data to refine the model, and
- provide tools that will enable healthcare stakeholders to cost-effectively develop and implement solutions to address patient needs and improve adherence rates.
Restricted Call to maximise impact of IMI2 JU objectives and scientific priorities (RIA)
Scope: The scope of the restricted call will be to support further research activities in those exceptional cases where it is necessary to enable successful consortia to build on the achievements of their initial action and move onto the next step of the challenge.
Restricted to the initial consortia of actions funded under topics published in the IMI2 JU Annual Work Plans of 2014, 2015 and 2016 since only these actions are sufficiently advanced in their implementation to be considered for follow-up activities.
Read about more grants in our Funding Helpdesk.